EP2248897A3 - Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes - Google Patents

Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes Download PDF

Info

Publication number
EP2248897A3
EP2248897A3 EP10174536A EP10174536A EP2248897A3 EP 2248897 A3 EP2248897 A3 EP 2248897A3 EP 10174536 A EP10174536 A EP 10174536A EP 10174536 A EP10174536 A EP 10174536A EP 2248897 A3 EP2248897 A3 EP 2248897A3
Authority
EP
European Patent Office
Prior art keywords
methods
osteoblasts
mammalian cells
undifferentiated mammalian
inducing differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10174536A
Other languages
German (de)
English (en)
Other versions
EP2248897A2 (fr
Inventor
Luc Juliaan Corina Van Rompaey
Peter Herwig Maria Tomme
Robin John Brown
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galapagos NV
Original Assignee
Galapagos NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos NV filed Critical Galapagos NV
Priority to EP10174536A priority Critical patent/EP2248897A3/fr
Publication of EP2248897A2 publication Critical patent/EP2248897A2/fr
Publication of EP2248897A3 publication Critical patent/EP2248897A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
EP10174536A 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes Withdrawn EP2248897A3 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP10174536A EP2248897A3 (fr) 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2003/014994 WO2005063983A1 (fr) 2003-12-29 2003-12-29 Modulateurs de l'homeostasie osseuse identifies dans un criblage a haut debit
EP10174536A EP2248897A3 (fr) 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes
EP04804467A EP1709173A2 (fr) 2003-12-29 2004-12-29 Methodes d'induction de la differenciation de cellules de mammifere non differentiees en osteoblastes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP04804467.1 Division 2004-12-29

Publications (2)

Publication Number Publication Date
EP2248897A2 EP2248897A2 (fr) 2010-11-10
EP2248897A3 true EP2248897A3 (fr) 2012-07-25

Family

ID=34717148

Family Applications (4)

Application Number Title Priority Date Filing Date
EP04804467A Withdrawn EP1709173A2 (fr) 2003-12-29 2004-12-29 Methodes d'induction de la differenciation de cellules de mammifere non differentiees en osteoblastes
EP10174533A Withdrawn EP2248896A3 (fr) 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes
EP20100174538 Withdrawn EP2248898A3 (fr) 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes
EP10174536A Withdrawn EP2248897A3 (fr) 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes

Family Applications Before (3)

Application Number Title Priority Date Filing Date
EP04804467A Withdrawn EP1709173A2 (fr) 2003-12-29 2004-12-29 Methodes d'induction de la differenciation de cellules de mammifere non differentiees en osteoblastes
EP10174533A Withdrawn EP2248896A3 (fr) 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes
EP20100174538 Withdrawn EP2248898A3 (fr) 2003-12-29 2004-12-29 Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes

Country Status (6)

Country Link
US (2) US7638288B2 (fr)
EP (4) EP1709173A2 (fr)
JP (1) JP5667333B2 (fr)
AU (1) AU2003300239A1 (fr)
CA (1) CA2551920A1 (fr)
WO (2) WO2005063983A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008030239A1 (fr) * 2006-09-05 2008-03-13 Sirna Therapeutics, Inc. inhibition par interférence ARN de l'expression GÉNÉTIQUE de l'histone désacétylase (HDAC) au moyen d'un petit acide nucléique interférent
AU2003300239A1 (en) 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
US20070004624A1 (en) * 2004-06-16 2007-01-04 Luc Van Rompaey Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions
US20070004658A1 (en) 2004-06-21 2007-01-04 Nick Vandeghinste Method and means for treatment of osteoarthritis
EP1734118A1 (fr) * 2005-06-15 2006-12-20 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Identification de gènes modulateurs de la voie de signalisation JAK/STAT par criblage du génome à l'aide d'ARNi
JP2007191467A (ja) * 2005-12-20 2007-08-02 Pentax Corp 肥大化能を有する軟骨細胞の産生する新しい細胞機能調節因子
AR057252A1 (es) * 2005-12-27 2007-11-21 Alcon Mfg Ltd Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares
CA2822302A1 (fr) * 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Procedes pour alterer la differenciation osteoclaste
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
WO2008128161A2 (fr) * 2007-04-13 2008-10-23 University Of Florida Research Foundation Inc. Identification de kinase à chaîne légère de myosine spécifique cardiaque
JP2010538244A (ja) 2007-06-20 2010-12-09 ガラパゴス・ナムローゼ・フェンノートシャップ 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法
US9040051B2 (en) * 2007-10-02 2015-05-26 Universitaet Zu Koeln Marker genes for regulatory T cells from human blood
US8506982B2 (en) * 2007-11-14 2013-08-13 Osteosphere, Llc Development of a human colloidal bone graft material
US20110091862A1 (en) * 2007-11-14 2011-04-21 Osteosphere, Llc Generation of an hla-negative osteogenic precursor cell line
KR101881596B1 (ko) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 인 원자 변형된 핵산의 합성 방법
SG10201403841QA (en) 2009-07-06 2014-09-26 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
WO2011105901A2 (fr) * 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonistes de composant du complément 9 (c9) et utilisations associées
WO2012012443A2 (fr) 2010-07-19 2012-01-26 Bennett C Frank Modulation de l'expression de la protéine kinase de la dystrophie myotonique (dmpk)
EP2620428B1 (fr) 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Groupe auxiliaire asymétrique
US9340584B2 (en) 2011-03-29 2016-05-17 The General Hospital Corporation Engineered thioredoxin-like fold proteins
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
US9598458B2 (en) 2012-07-13 2017-03-21 Wave Life Sciences Japan, Inc. Asymmetric auxiliary group
TWI460274B (zh) * 2012-07-24 2014-11-11 Univ Nat Yang Ming 偵測ＲＯＣＫｓ活化之試劑
CN108949694B (zh) 2012-09-11 2022-06-17 康宁有限公司 瞬时过表达编码药物转运蛋白和/或药物代谢酶的基因的可消耗的低温保存的细胞
TW201536329A (zh) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
EP3058068B1 (fr) * 2013-10-14 2019-04-24 Ionis Pharmaceuticals, Inc. Compositions destinées à moduler l'expression du transcrit antisens c9orf72
BR112016016400A2 (pt) 2014-01-16 2017-10-03 Wave Life Sciences Ltd Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos
US10793855B2 (en) 2015-01-06 2020-10-06 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of C9ORF72 antisense transcript
CA3012820A1 (fr) 2015-02-13 2016-08-18 The Board Of Trustees Of The University Of Illinois Inhibition peptidique des maladies ou affections mediees par le ccr3
WO2016167780A1 (fr) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions destinées à moduler l'expression du transcrit antisens c9orf72
CN109456968B (zh) * 2018-12-29 2022-10-04 上海奕谱生物科技有限公司 基于甲基化修饰的肿瘤标记物
TW202204616A (zh) * 2020-03-30 2022-02-01 美商瑞新生物科技公司 阿茲海默症的治療
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012070A2 (fr) * 2001-08-03 2003-02-13 Gene Logic, Inc. Gene associe a des troubles osseux
WO2004094636A1 (fr) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Constructions demontables effectives d'arnsi

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
PT2261335T (pt) * 1998-11-27 2017-09-08 Ucb Pharma Sa Composições e métodos para aumentar a mineralização óssea
CA2402392A1 (fr) * 2000-04-07 2001-10-18 Arena Pharmaceuticals, Inc. Recepteurs connus couples a la proteine g non endogenes a activation constitutive
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
US7332337B2 (en) * 2000-05-16 2008-02-19 Galapagos Nv Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US20030186360A1 (en) * 2000-09-27 2003-10-02 Feder John N. Novel human G-protein coupled receptor, HGPRBMY3, expressed highly in immune -and colon-related tissues
JP2005503792A (ja) * 2001-08-22 2005-02-10 ガラパゴス・ジェノミックス・ナムローゼ・フェンノートシャップ ハイ・スループット・スクリーニングにおいて同定される骨の恒常性のモジュレーター
US20030198627A1 (en) * 2001-09-01 2003-10-23 Gert-Jan Arts siRNA knockout assay method and constructs
US20040101818A1 (en) * 2001-12-18 2004-05-27 Darren Ji Gene expression profiles associated with osteoblast differentiation
EP1364968A1 (fr) * 2002-05-23 2003-11-26 Bayer Aktiengesellschaft Diagnostic et traitement des maladies associées au récepteur 1 d'arginine-vasopressine (AVPR1)
US20040209808A1 (en) * 2003-02-11 2004-10-21 Kornacker Michael G. Modulators of human G-protein coupled receptors
MXPA05013115A (es) * 2003-06-06 2006-05-25 Wyeth Corp Metodos y materiales para identificar agentes que modulan la remodelacion de hueso y agentes identificados por los mismos.
AU2003300239A1 (en) 2003-12-29 2005-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
US20070004624A1 (en) * 2004-06-16 2007-01-04 Luc Van Rompaey Methods for modulating bone tissue formation, orthogenic agents and pharmaceutical compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012070A2 (fr) * 2001-08-03 2003-02-13 Gene Logic, Inc. Gene associe a des troubles osseux
WO2004094636A1 (fr) * 2003-04-24 2004-11-04 Galapagos Genomics N.V. Constructions demontables effectives d'arnsi

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARTS GERT-JAN ET AL: "Adenoviral vectors expressing siRNAs for discovery and validation of gene function.", GENOME RESEARCH, vol. 13, no. 10, October 2003 (2003-10-01), pages 2325 - 2332, XP002298666, ISSN: 1088-9051 *
MICHIELS FRITS ET AL: "Arrayed adenoviral expression libraries for functional screening", NATURE BIOTECHNOLOGY, vol. 20, no. 11, November 2002 (2002-11-01), pages 1154 - 1157, XP002298665, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
EP2248898A2 (fr) 2010-11-10
WO2005063976A3 (fr) 2005-12-15
US8338124B2 (en) 2012-12-25
WO2005063983A1 (fr) 2005-07-14
EP1709173A2 (fr) 2006-10-11
WO2005063976A2 (fr) 2005-07-14
US20070031940A1 (en) 2007-02-08
EP2248896A3 (fr) 2012-07-25
EP2248896A2 (fr) 2010-11-10
AU2003300239A1 (en) 2005-07-21
JP5667333B2 (ja) 2015-02-12
EP2248897A2 (fr) 2010-11-10
US7638288B2 (en) 2009-12-29
EP2248898A3 (fr) 2012-07-25
CA2551920A1 (fr) 2005-07-14
JP2007516714A (ja) 2007-06-28
US20100093833A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
EP2248898A3 (fr) Méthodes d'induction de la différenciation de cellules de mammifère non différentiées en ostéoblastes
EP2360474A3 (fr) Méthodes et moyens pour le traitement de l'ostéoarthrite
EP2283847A3 (fr) Traitement de maladie au moyen de cellules mourantes ou mortes
EP2239328A3 (fr) Procédés et compositions pour traiter une maladie neurologique
EP2293076A3 (fr) Procédé de stratification du risque chez des patients ayant une maladie primaire non infectieuse
EP2266636A3 (fr) Implant médical polyvalent
EP2230319A3 (fr) Marqueurs d'expression génique pour pronostiquer le cancer du sein
EP2517727A3 (fr) Biomarqueurs pour la sclérose en plaques et procédés d'utilisation de ceux-ci
EP2319531A3 (fr) Stimulation de la proliferation de cellules souches pluripotentes par administration de composés associés à la gestation
PT1567667E (pt) Tratamento da doença de huntington com epa
EP1745739A3 (fr) Imagerie optique de la polyarthrite rhumatoïde
EP2441847A3 (fr) Methodes de criblage utilisant syk en combinaison avec la proteine tau
WO2004011603A3 (fr) Cardiomyocytes fonctionnels provenant de cellules souches embryonnaires humaines
EP2503338A3 (fr) CD73 comme biomarqueur pour surveiller le développement de maladies et évaluer l'efficacité des thérapies
WO2003050271A3 (fr) Production in vitro de cellules dendritiques a partir de monocytes cd14+ en particulier pour la preparation de modeles tissulaires et/ou cellulaires monocouches et tridimensionnels, ainsi que l'utilisation de ces modeles
EP2365335A3 (fr) Procédé de diagnostic
EP1895017A3 (fr) Utilisation d'antigènes A33 et de blocage
AU2002331356A1 (en) Nanoparticles for dna administration to a target organ
USD492997S1 (en) Confocal microscope having a positionable imaging head for cellular imaging of skin, other living tissue and biological processes
WO2004104591A3 (fr) Ameliorations apportees a une therapie induite par des lymphocytes t gamma-delta
EP2617809A3 (fr) Cellules souches neurales
Tsukanaka et al. Evaluation of bioactivity of alkali-and heat-treated titanium using fluorescent mouse osteoblasts
Tortiglione An ancient model organism to test in vivo novel functional nanocrystals
EP1696028A3 (fr) Compositions et méthodes pour la thérapie et le diagnostic du cancer du sein
ZA200603236B (en) Methods for the preparation of {2-[8,9-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100830

AC Divisional application: reference to earlier application

Ref document number: 1709173

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BROWN, ROBIN JOHN

Inventor name: TOMME, PETER HERWIG MARIA

Inventor name: VAN ROMPAEY, LUC JULIAAN CORINA

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/08 20060101ALN20120620BHEP

Ipc: C12Q 1/68 20060101ALI20120620BHEP

Ipc: G01N 33/68 20060101ALI20120620BHEP

Ipc: A61K 31/713 20060101ALI20120620BHEP

Ipc: C12N 15/113 20100101AFI20120620BHEP

Ipc: A61P 19/10 20060101ALN20120620BHEP

Ipc: C12N 5/10 20060101ALI20120620BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130126